PACIRA PHARMACEUTICALS INC's ticker is PCRX and the CUSIP is 695127100. A total of 266 filers reported holding PACIRA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 1.94 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,786,910 | -46.3% | 90,838 | -29.8% | 0.00% | -100.0% |
| Q2 2023 | $5,186,260 | +51.5% | 129,430 | +54.3% | 0.00% | – |
| Q1 2023 | $3,424,000 | +111285.8% | 83,897 | +5.3% | 0.00% | – |
| Q4 2022 | $3,074 | -99.9% | 79,644 | +0.3% | 0.00% | -100.0% |
| Q3 2022 | $4,226,000 | +3.0% | 79,440 | +12.8% | 0.00% | 0.0% |
| Q2 2022 | $4,104,000 | -11.7% | 70,406 | +15.6% | 0.00% | 0.0% |
| Q1 2022 | $4,647,000 | +49.9% | 60,888 | +18.1% | 0.00% | – |
| Q4 2021 | $3,101,000 | +8.6% | 51,538 | +1.1% | 0.00% | – |
| Q3 2021 | $2,855,000 | -11.1% | 50,968 | -3.7% | 0.00% | – |
| Q2 2021 | $3,212,000 | -14.4% | 52,931 | -1.1% | 0.00% | -100.0% |
| Q1 2021 | $3,751,000 | +40.2% | 53,518 | +19.7% | 0.00% | – |
| Q4 2020 | $2,676,000 | -12.6% | 44,715 | -13.3% | 0.00% | -100.0% |
| Q3 2020 | $3,063,000 | +179.0% | 51,572 | +146.5% | 0.00% | – |
| Q2 2020 | $1,098,000 | +32.9% | 20,923 | -15.1% | 0.00% | – |
| Q1 2020 | $826,000 | -28.7% | 24,643 | -3.6% | 0.00% | – |
| Q4 2019 | $1,158,000 | +32.5% | 25,556 | +11.4% | 0.00% | – |
| Q3 2019 | $874,000 | -87.4% | 22,950 | -85.5% | 0.00% | -100.0% |
| Q2 2019 | $6,942,000 | +1212.3% | 158,013 | +1036.4% | 0.00% | – |
| Q1 2019 | $529,000 | -14.0% | 13,905 | -2.9% | 0.00% | – |
| Q4 2018 | $615,000 | +26.8% | 14,314 | +44.8% | 0.00% | – |
| Q3 2018 | $485,000 | +74.5% | 9,882 | +14.1% | 0.00% | – |
| Q2 2018 | $278,000 | +4.5% | 8,664 | +1.4% | 0.00% | – |
| Q1 2018 | $266,000 | -95.7% | 8,543 | -93.7% | 0.00% | -100.0% |
| Q4 2017 | $6,211,000 | -18.8% | 136,062 | -31.2% | 0.00% | -50.0% |
| Q3 2017 | $7,651,000 | -9.1% | 197,702 | +12.1% | 0.00% | 0.0% |
| Q2 2017 | $8,416,000 | +20.9% | 176,425 | +15.5% | 0.00% | 0.0% |
| Q1 2017 | $6,964,000 | +5.9% | 152,725 | -25.0% | 0.00% | 0.0% |
| Q4 2016 | $6,575,000 | +8.7% | 203,563 | +15.2% | 0.00% | +100.0% |
| Q3 2016 | $6,048,000 | +90.7% | 176,725 | +88.0% | 0.00% | 0.0% |
| Q2 2016 | $3,172,000 | -56.5% | 94,024 | -31.6% | 0.00% | -50.0% |
| Q1 2016 | $7,285,000 | -32.0% | 137,491 | -1.5% | 0.00% | -33.3% |
| Q4 2015 | $10,716,000 | +65.7% | 139,543 | -11.3% | 0.00% | +50.0% |
| Q3 2015 | $6,469,000 | -57.1% | 157,397 | -26.1% | 0.00% | -50.0% |
| Q2 2015 | $15,067,000 | +92.1% | 213,047 | +141.3% | 0.00% | +100.0% |
| Q1 2015 | $7,845,000 | -28.1% | 88,275 | -28.3% | 0.00% | 0.0% |
| Q4 2014 | $10,908,000 | -58.8% | 123,037 | -55.0% | 0.00% | -66.7% |
| Q3 2014 | $26,482,000 | -17.0% | 273,247 | -21.4% | 0.01% | -25.0% |
| Q2 2014 | $31,924,000 | +39.6% | 347,530 | +6.4% | 0.01% | +33.3% |
| Q1 2014 | $22,871,000 | +49.4% | 326,759 | +22.7% | 0.01% | +50.0% |
| Q4 2013 | $15,305,000 | +7.3% | 266,205 | -10.3% | 0.00% | 0.0% |
| Q3 2013 | $14,269,000 | +84.4% | 296,795 | +11.2% | 0.00% | +100.0% |
| Q2 2013 | $7,738,000 | – | 266,799 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gagnon Advisors, LLC | 251,140 | $19,167,000 | 8.83% |
| GAGNON SECURITIES LLC | 610,933 | $46,626,000 | 7.60% |
| Tamarack Advisers, LP | 205,000 | $15,646,000 | 7.40% |
| Spyglass Capital Management LLC | 1,871,040 | $142,798,000 | 4.88% |
| Lisanti Capital Growth, LLC | 302,413 | $23,080,000 | 2.59% |
| Rock Springs Capital Management LP | 1,000,000 | $76,320,000 | 1.92% |
| MESIROW FINANCIAL INVESTMENT MANAGEMENT - Fixed Income | 208,197 | $15,890,000 | 1.76% |
| JABODON PT CO | 49,052 | $3,744,000 | 1.70% |
| Zweig-DiMenna Associates LLC | 166,675 | $12,721,000 | 1.70% |
| NEUMEIER POMA INVESTMENT COUNSEL LLC | 317,425 | $24,226,000 | 1.63% |